Sacituzumab Tirumotecan (sac-TMT)

DRUG3 trials

Sponsors

Merck Sharp & Dohme LLC, Fudan University

Conditions

Adjuvant Drug TherapyBrain MetastasisEsophageal CancerEsophageal NeoplasmsGastroesophageal AdenocarcinomaGastroesophageal JunctionTNBC

Phase 1

Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)

RecruitingNCT06469944

Merck Sharp & Dohme LLCEsophageal Cancer, Esophageal Neoplasms, Gastroesophageal Adenocarcinoma +1

Start: 2024-09-20End: 2029-09-12Target: 160Updated: 2026-05-26

Phase 2

Sac-TMT Combined With Bevacizumab in TNBC With Brain Metastases

RecruitingNCT07623577

Fudan UniversityBrain Metastasis, TNBC

Start: 2026-01-01End: 2027-12-01Target: 24Updated: 2026-06-03

Phase 3

Sac-TMT Sequential Capecitabine Versus Capecitabine in Early-Stage High-Risk Triple-Negative Breast Cancer Without BRCA Mutations

Not yet recruitingNCT07628504

Fudan UniversityAdjuvant Drug Therapy

Start: 2026-05-18End: 2035-03-30Target: 420Updated: 2026-06-05

Related Papers

KEYMAKER-U06: Phase 1/2 umbrella platform study of TROP2 antibody-drug conjugate sacituzumab tirumotecan plus pembrolizumab plus chemotherapy (substudy 06C) and sacituzumab tirumotecan plus paclitaxel (substudy 06D) in gastroesophageal adenocarcinoma.

Journal of Clinical Oncology2025-01-27